Skip to main content

Advertisement

Log in

Modeling stroke management: a qualitative review of cost-effectiveness analyses

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Objective

To review recent economic analyses and determine if means of improving methodology used in modeling stroke management may exist.

Study design and setting

The Medline database was searched for pharmacoeconomic models of treatments or interventions in acute, non-transitory ischemic stroke. Search terms were: stroke, cost, cost-effectiveness, cost analysis, stroke management, model, modeling, and economic. All English-language articles published from January 1997 to January 2008 were reviewed.

Results

Ten Markov models and three decision analytical models were identified. All models had a societal perspective and all but one had lifetime horizons. They were all based on common patient states of disability, mortality and recurrence of stroke. Inputs used in the models were transparent and valid. Intracranial hemorrhage, cardiovascular events and data closely related to local settings were not systematically considered. One-way sensitivity analyses were the most common, but few parameters were tested and these varied between models. Consensus key drivers were therefore difficult to determine.

Conclusion

The overall structure of the models reviewed was sound. However, they should include more systematically cardiovascular events and intracranial hemorrhage, as well as local epidemiological data. Further multi-way sensitivity analyses would help to identify key cost drivers with greater precision and robustness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S.M., Ho, M., Howard, V., Kissela, B., Kittner, S., Lloyd-Jones, D., McDermott, M., Meigs, J., Moy, C., Nichol, G., O’Donnell, C., Roger, V., Sorlie, P., Steinberger, J., Thom, T., Wilson, M., Hong, Y.: Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), 25–146 (2008)

    Article  Google Scholar 

  2. Wolfe, C.D., Giroud, M., Kolominsky-Rabas, P., Dundas, R., Lemesle, M., Heuschmann, P., Rudd, A.: Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke 31(9), 2074–2079 (2000)

    Google Scholar 

  3. Mayo, N.E., Wood-Dauphinee, S., Ahmed, S., Gordon, C., Higgins, J., McEwen, S., Salbach, N.: Disablement following stroke. Disabil. Rehabil. 21(5–6), 258–268 (1999)

    Google Scholar 

  4. Van Den Bos, G.A.M.: The burden of chronic diseases in terms of disability, use of health care and healthy life expectancies. Eur. J. Public Health 5(1), 29–34 (1995)

    Article  Google Scholar 

  5. Patel, M.D., Tilling, K., Lawrence, E., Rudd, A.G., Wolfe, C.D., McKevitt, C.: Relationships between long-term stroke disability, handicap and health-related quality of life. Age Ageing 35(3), 273–279 (2006)

    Article  Google Scholar 

  6. Haacke, C., Althaus, A., Spottke, A., Siebert, U., Back, T., Dodel, R.: Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 37(1), 193–198 (2006)

    Article  Google Scholar 

  7. Pohjasvaara, T., Vataja, R., Leppavuori, A., Kaste, M., Erkinjuntti, T.: Cognitive functions and depression as predictors of poor outcome 15 months after stroke. Cerebrovasc. Dis. 14(3–4), 228–233 (2002)

    Article  Google Scholar 

  8. Kolominsky-Rabas, P.L., Heuschmann, P.U., Marschall, D., Emmert, M., Baltzer, N., Neundorfer, B., Schoffski, O., Krobot, K.J.: Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen stroke project. Stroke 37(5), 1179–1183 (2006)

    Article  Google Scholar 

  9. Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J., Lewis, S., Lindley, R., Neilson, A., Thomas, B., Wardlaw, J.: A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol. Assess. 6(26), 1–112 (2002)

    Google Scholar 

  10. Chambers, M.G., Koch, P., Hutton, J.: Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 5(2), 82–97 (2002)

    Article  Google Scholar 

  11. Ehlers, L., Andersen, G., Clausen, L.B., Bech, M., Kjolby, M.: Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 38(1), 85–89 (2007)

    Article  Google Scholar 

  12. Ehlers, L., Muskens, W.M., Jensen, L.G., Kjolby, M., Andersen, G.: National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs 22(1), 73–81 (2008)

    Article  Google Scholar 

  13. Fagan, S.C., Morgenstern, L.B., Petitta, A., Ward, R.E., Tilley, B.C., Marler, J.R., Levine, S.R., Broderick, J.P., Kwiatkowski, T.G., Frankel, M., Brott, T.G., Walker, M.D.: Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA stroke study group. Neurology 50(4), 883–890 (1998)

    Google Scholar 

  14. Hallan, S., Asberg, A., Indredavik, B., Wideroe, T.E.: A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. J. Intern. Med. 246(6), 549–559 (1999)

    Article  Google Scholar 

  15. Launois, R., Giroud, M., Megnigbeto, A.C., Le Lay, K., Presente, G., Mahagne, M.H., Durand, I., Gaudin, A.F.: Estimating the cost-effectiveness of stroke units in France compared with conventional care. Stroke 35(3), 770–775 (2004)

    Article  Google Scholar 

  16. Mar, J., Begiristain, J.M., Arrazola, A.: Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc. Dis. 20(3), 193–200 (2005)

    Article  Google Scholar 

  17. Mihalopoulos, C., Cadilhac, D.A., Moodie, M.L., Dewey, H.M., Thrift, A.G., Donnan, G.A., Carter, R.C.: Development and application of model of resource utilization, costs, and outcomes for stroke (MORUCOS): an Australian economic model for stroke. Int. J. Technol. Assess. Health Care 21(4), 499–505 (2005)

    Article  Google Scholar 

  18. Samsa, G.P., Reutter, R.A., Parmigiani, G., Ancukiewicz, M., Abrahamse, P., Lipscomb, J., Matchar, D.B.: Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol. 52(3), 259–271 (1999)

    Article  Google Scholar 

  19. Samsa, G.P., Matchar, D.B., Williams, G.R., Levy, D.E.: Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the stroke treatment with ancrod trial (STAT). J. Eval. Clin. Pract. 8(1), 61–70 (2002)

    Article  Google Scholar 

  20. Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J., Lewis, S., Lindley, R., Neilson, A., Wardlaw, J.: Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35(6), 1490–1497 (2004)

    Article  Google Scholar 

  21. Sinclair, S.E., Frighetto, L., Loewen, P.S., Sunderji, R., Teal, P., Fagan, S.C., Marra, C.A.: Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19(9), 927–936 (2001)

    Article  Google Scholar 

  22. Wardlaw, J.M., Seymour, J., Cairns, J., Keir, S., Lewis, S., Sandercock, P.: Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 35(11), 2477–2483 (2004)

    Article  Google Scholar 

  23. Bonita, R., Beaglehole, R.: Recovery of motor function after stroke. Stroke 19(12), 1497–1500 (1988)

    Google Scholar 

  24. Collin, C., Wade, D.T., Davies, S., Horne, V.: The Barthel ADL index: a reliability study. Int. Disabil. Stud. 10(2), 61–63 (1988)

    Google Scholar 

  25. Gresham, G.E., Phillips, T.F., Labi, M.L.: ADL status in stroke: relative merits of three standard indexes. Arch. Phys. Med. Rehabil. 61(8), 355–358 (1980)

    Google Scholar 

  26. Loewen, S.C., Anderson, B.A.: Predictors of stroke outcome using objective measurement scales. Stroke 21(1), 78–81 (1990)

    Google Scholar 

  27. Mahoney, F.I., Barthel, D.W.: Functional evaluation: the barthel index. Md. State Med. J. 14, 61–65 (1965)

    Google Scholar 

  28. Rankin, J.: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott. Med. J. 2(5), 200–215 (1957)

    Google Scholar 

  29. van Swieten, J.C., Koudstaal, P.J., Visser, M.C., Schouten, H.J., van Gijn, J.: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5), 604–607 (1988)

    Google Scholar 

  30. Briggs, A., Claxton, K., Sculpher, M.: Decision modelling for health economic evaluation (Handbooks in health economic evaluation). Oxford University Press, Oxford (2006)

    Google Scholar 

  31. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)

    Google Scholar 

  32. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581–1587 (1995)

    Article  Google Scholar 

  33. Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G., Mahagne, M.H., et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13), 1017–1025 (1995)

    Article  Google Scholar 

  34. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., Trouillas, P.: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 352(9136), 1245–1251 (1998)

    Article  Google Scholar 

  35. Gage, B.F., Cardinalli, A.B., Owens, D.K.: The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch. Intern. Med. 156(16), 1829–1836 (1996)

    Article  Google Scholar 

  36. Solomon, N.A., Glick, H.A., Russo, C.J., Lee, J., Schulman, K.A.: Patient preferences for stroke outcomes. Stroke 25(9), 1721–1725 (1994)

    Google Scholar 

  37. Lee, A.J., Huber, J., Stason, W.B.: Post stroke rehabilitation in older Americans. The medicare experience. Med. Care 34(8), 811–825 (1996)

    Article  Google Scholar 

  38. Weiner, J.M., Illston, L.H., Hanley, R.J.: Sharing the burden: strategies for public and private long-term care insurance. Brokings Institute, Washington, DC (1993)

    Google Scholar 

  39. Hallan, S., Asberg, A., Indredavik, B., Wideroe, T.E.: Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J. Intern. Med. 246(3), 309–316 (1999)

    Article  Google Scholar 

  40. Wardlaw J.M., Zoppo G., Yamaguchi T., Berge E.: Thrombolysis for acute ischaemic stroke. Cochrane database. Syst. Rev. 3, CD000213 (2003)

  41. Kwiatkowski, T.G., Libman, R.B., Frankel, M., Tilley, B.C., Morgenstern, L.B., Lu, M., Broderick, J.P., Lewandowski, C.A., Marler, J.R., Levine, S.R., Brott, T.: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N. Engl. J. Med. 340(23), 1781–1787 (1999)

    Article  Google Scholar 

  42. Dewey, H.M., Thrift, A.G., Mihalopoulos, C., Carter, R., Macdonell, R.A., McNeil, J.J., Donnan, G.A.: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 32(10), 2409–2416 (2001)

    Article  Google Scholar 

  43. Samsa, G.P., Matchar, D.B., Goldstein, L., Bonito, A., Duncan, P.W., Lipscomb, J., Enarson, C., Witter, D., Venus, P., Paul, J.E., Weinberger, M.: Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am. Heart J. 136(4 Pt 1), 703–713 (1998)

    Article  Google Scholar 

  44. Sherman, D.G., Atkinson, R.P., Chippendale, T., Levin, K.A., Ng, K., Futrell, N., Hsu, C.Y., Levy, D.E.: Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke treatment with ancrod trial. JAMA 283(18), 2395–2403 (2000)

    Article  Google Scholar 

  45. Counsell, C., Dennis, M., McDowall, M., Warlow, C.: Predicting outcome after acute and subacute stroke: development and validation of new prognostic models. Stroke 33(4), 1041–1047 (2002)

    Article  Google Scholar 

  46. Dorman, P., Dennis, M., Sandercock, P.: Are the modified “simple questions” a valid and reliable measure of health related quality of life after stroke? United Kingdom collaborators in the international stroke trial. J. Neurol. Neurosurg. Psychiatry 69(4), 487–493 (2000)

    Article  Google Scholar 

Download references

Acknowledgments

The authors wish to acknowledge the editorial assistance of Guillaume Hébert, PhD, in the research and production of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Delphine Saragoussi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guilhaume, C., Saragoussi, D., Cochran, J. et al. Modeling stroke management: a qualitative review of cost-effectiveness analyses. Eur J Health Econ 11, 419–426 (2010). https://doi.org/10.1007/s10198-010-0228-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-010-0228-4

Keywords

JEL Classification

Navigation